Research & Development
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
2 October 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), which develops medicines across neuroscience and immunology, on Friday released new anal...
PearlMatrix P-15 Peptide Enhanced Bone Graft receives Medicare New Technology Add-on Payment (NTAP) status
2 October 2026 - Cerapedics Inc., a US-based, commercial-stage musculoskeletal company involved in bone repair, announced on Thursday that the Centers for Medicare & Medicaid Services (CMS) has gr...
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its N...
DBV Technologies submits FDA application for VIASKIN Peanut Patch in children
30 September 2026 - Late-stage biopharmaceutical company DBV Technologies (Euronext:DBV) (Nasdaq:DBVT) announced on Wednesday that it has submitted a Biologics License Application to the US Food and D...
UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation
30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1...
Vanda Pharmaceuticals reports positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder
30 September 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) on Tuesday reported positive topline results from its pivotal Phase III study of HETLIOZ (tasimelteon) 20mg in adu...